Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases
- PMID: 35462989
- PMCID: PMC9023861
- DOI: 10.3389/fmed.2022.849086
Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases
Abstract
This review describes the complex interplay between inflammation, vasculopathy and fibrosis that involve the heart and peripheral small vessels, leading to endothelial stiffness, vascular damage, and early aging in patients with systemic lupus erythematosus and systemic sclerosis, which represents two different models of vascular dysfunction among systemic autoimmune diseases. In fact, despite the fact that diagnostic methods and therapies have been significantly improved in the last years, affected patients show an excess of cardiovascular mortality if compared with the general population. In addition, we provide a complete overview on the new techniques which are used for the evaluation of endothelial dysfunction in a preclinical phase, which could represent a new approach in the assessment of cardiovascular risk in these patients.
Keywords: endothelial dysfunction; microvascular disease; systemic lupus erythematosus; systemic sclerosis; techniques of assessment.
Copyright © 2022 Moschetti, Piantoni, Vizzardi, Sciatti, Riccardi, Franceschini and Cavazzana.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Cardiovascular disease in systemic sclerosis.Ann Transl Med. 2015 Jan;3(1):8. doi: 10.3978/j.issn.2305-5839.2014.12.12. Ann Transl Med. 2015. PMID: 25705640 Free PMC article. Review.
-
Endothelial Dysfunction in Systemic Lupus Erythematosus: Pathogenesis, Assessment and Therapeutic Opportunities.Rev Recent Clin Trials. 2018;13(3):192-198. doi: 10.2174/1574887113666180314091831. Rev Recent Clin Trials. 2018. PMID: 29542419 Review.
-
Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis.Circulation. 2009 Dec 8;120(23):2367-76. doi: 10.1161/CIRCULATIONAHA.109.855114. Epub 2009 Nov 23. Circulation. 2009. PMID: 19933934
-
Endothelial Dysfunction in Early Systemic Lupus Erythematosus Patients and Controls Without Previous Cardiovascular Events.Arthritis Care Res (Hoboken). 2018 Sep;70(9):1277-1283. doi: 10.1002/acr.23495. Epub 2018 Aug 16. Arthritis Care Res (Hoboken). 2018. PMID: 29245186
-
Evaluation of hypertension in systemic sclerosis and systemic lupus erythematosus overlap.J Scleroderma Relat Disord. 2023 Feb;8(1):14-19. doi: 10.1177/23971983221122673. Epub 2022 Sep 14. J Scleroderma Relat Disord. 2023. PMID: 36743818 Free PMC article. Review.
Cited by
-
The role of asymmetric dimethylarginine in endothelial dysfunction and abnormal nitric oxide metabolism in systemic sclerosis: results from a pilot study.Clin Rheumatol. 2023 Apr;42(4):1077-1085. doi: 10.1007/s10067-022-06472-w. Epub 2022 Dec 19. Clin Rheumatol. 2023. PMID: 36534350
-
Modulating Nitric Oxide: Implications for Cytotoxicity and Cytoprotection.Antioxidants (Basel). 2024 Apr 23;13(5):504. doi: 10.3390/antiox13050504. Antioxidants (Basel). 2024. PMID: 38790609 Free PMC article. Review.
-
Biomarkers in Systemic Lupus Erythematosus along with Metabolic Syndrome.J Clin Med. 2024 Mar 29;13(7):1988. doi: 10.3390/jcm13071988. J Clin Med. 2024. PMID: 38610754 Free PMC article. Review.
-
Neurological Manifestations of Systemic Lupus Erythematosus: A Comprehensive Review.Cureus. 2025 Feb 24;17(2):e79569. doi: 10.7759/cureus.79569. eCollection 2025 Feb. Cureus. 2025. PMID: 40151747 Free PMC article. Review.
-
Type I Interferons induce endothelial destabilization in Systemic Lupus Erythematosus in a Tie2-dependent manner.Front Immunol. 2023 Dec 14;14:1277267. doi: 10.3389/fimmu.2023.1277267. eCollection 2023. Front Immunol. 2023. PMID: 38162654 Free PMC article.
References
-
- Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. (2017) 76:17–28. 10.1136/annrheumdis-2016-209775 - DOI - PubMed
-
- Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. (2001) 44:2331–7. 10.1002/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources